NeuroThera Labs Inc. completed two non-brokered private placement tranches that raised aggregate gross proceeds of C$5.4 million, including a final tranche in which SciSparc Ltd. invested C$2.7 million for 22.5 million units priced at C$0.12 each. Each unit consists of one common share and one warrant exercisable for three years, with part of the warrants subject to accelerated expiry if NeuroThera's securities are approved for trading on Nasdaq. Following the financing, SciSparc said it will hold about 44.6% of NeuroThera's issued and outstanding common shares. NeuroThera said it plans to use the proceeds for working capital and corporate and administrative expenses.